E. M. Piall

663 total citations
17 papers, 527 citations indexed

About

E. M. Piall is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Genetics. According to data from OpenAlex, E. M. Piall has authored 17 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Public Health, Environmental and Occupational Health, 8 papers in Hematology and 6 papers in Genetics. Recurrent topics in E. M. Piall's work include Acute Lymphoblastic Leukemia research (12 papers), Acute Myeloid Leukemia Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). E. M. Piall is often cited by papers focused on Acute Lymphoblastic Leukemia research (12 papers), Acute Myeloid Leukemia Research (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). E. M. Piall collaborates with scholars based in United Kingdom, Australia and Singapore. E. M. Piall's co-authors include G. Wynne Aherne, V. Marks, A. E. Johnston, M L Slevin, Tim Lister, V.J. Harvey, William F. White, G. P. Mould, Vaille Dawson and Jette Ford and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and British Journal of Anaesthesia.

In The Last Decade

E. M. Piall

17 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. M. Piall United Kingdom	11	177	142	141	128	121	17	527
Daniel M. Lane United States	15	298 1.7×	103 0.7×	113 0.8×	134 1.0×	59 0.5×	28	707
M Tasso Spain	11	184 1.0×	87 0.6×	79 0.6×	144 1.1×	41 0.3×	23	423
Owens Ah United States	11	40 0.2×	156 1.1×	110 0.8×	106 0.8×	55 0.5×	21	550
Z. R. Desai United Kingdom	10	44 0.2×	194 1.4×	82 0.6×	126 1.0×	55 0.5×	15	397
Suzanne Monjanel‐Mouterde France	13	101 0.6×	109 0.8×	55 0.4×	58 0.5×	37 0.3×	22	408
A Marmont Italy	7	36 0.2×	174 1.2×	57 0.4×	338 2.6×	72 0.6×	12	649
Michael Katzenstein United States	6	42 0.2×	54 0.4×	102 0.7×	144 1.1×	55 0.5×	6	421
Victor Ginsberg United States	9	107 0.6×	36 0.3×	54 0.4×	178 1.4×	145 1.2×	21	647
Herman A. Godwin United States	14	51 0.3×	85 0.6×	174 1.2×	81 0.6×	68 0.6×	18	606
Myke R. Green United States	11	77 0.4×	155 1.1×	81 0.6×	40 0.3×	30 0.2×	24	396

Countries citing papers authored by E. M. Piall

Since Specialization

Citations

This map shows the geographic impact of E. M. Piall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. M. Piall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. M. Piall more than expected).

Fields of papers citing papers by E. M. Piall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. M. Piall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. M. Piall. The network helps show where E. M. Piall may publish in the future.

Co-authorship network of co-authors of E. M. Piall

This figure shows the co-authorship network connecting the top 25 collaborators of E. M. Piall. A scholar is included among the top collaborators of E. M. Piall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. M. Piall. E. M. Piall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kees, Ursula R., Jette Ford, Vaille Dawson, E. M. Piall, & G. Wynne Aherne. (1989). Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.. PubMed. 49(11). 3015–9. 41 indexed citations

Ganesan, Trivadi S., Michael J. Barnett, R. Amos, et al.. (1987). Cytosine arabinoside in the management of recurrent leukaemia. Hematological Oncology. 5(1). 65–69. 4 indexed citations

Slevin, M L, E. M. Piall, A. E. Johnston, et al.. (1984). The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension. Investigational New Drugs. 2(3). 271–276. 3 indexed citations

Slevin, M L, E. M. Piall, G. Wynne Aherne, A. E. Johnston, & Tim Lister. (1983). The Clinical Pharmacology of Cytosine Arabinoside. Hämatologie und Bluttransfusion. 28. 70–75. 4 indexed citations

Slevin, M L, E. M. Piall, G. Wynne Aherne, A. E. Johnston, & Tim Lister. (1983). Subcutaneous infusion of cytosine arabinoside. Cancer Chemotherapy and Pharmacology. 10(2). 112–114. 9 indexed citations

Slevin, M L, E. M. Piall, G. Wynne Aherne, et al.. (1983). Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.. Journal of Clinical Oncology. 1(9). 546–551. 127 indexed citations

Johnston, A. E., et al.. (1983). Relationship between Protein Binding and Extravascular drug Concentrations of a Water-soluble Drug, Cytosine Arabinoside. Journal of the Royal Society of Medicine. 76(5). 365–368. 7 indexed citations

Slevin, M L, E. M. Piall, G. Wynne Aherne, A. E. Johnston, & Tim Lister. (1982). The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Medical and Pediatric Oncology. 10(S1). 157–168. 54 indexed citations

Piall, E. M., G. Wynne Aherne, & V. Marks. (1982). Evaluation of a commercially available radioimmunoassay kit for measurement of doxorubicin in plasma.. PubMed. 28(1). 119–21. 8 indexed citations

10.

Hanks, G.W., et al.. (1981). CONTROLLED-RELEASE MORPHINE TABLETS. British Journal of Anaesthesia. 53(12). 1259–1264. 33 indexed citations

11.

Slevin, Mark, et al.. (1981). The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.. British Journal of Clinical Pharmacology. 12(4). 507–510. 20 indexed citations

12.

Piall, E. M., G. Wynne Aherne, & V. Marks. (1979). A radioimmunoassay for cytosine arabinoside. British Journal of Cancer. 40(4). 548–556. 43 indexed citations

13.

Aherne, G. Wynne, V. Marks, G. P. Mould, E. M. Piall, & William F. White. (1978). The interaction between methotrexate and probenecid in man [proceedings].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(2). 369P–369P. 10 indexed citations

14.

Aherne, G. Wynne, E. M. Piall, V. Marks, G. P. Mould, & William F. White. (1978). Prolongation and enhancement of serum methotrexate concentrations by probenecid.. BMJ. 1(6120). 1097–1099. 86 indexed citations

15.

Aherne, G. Wynne, E. M. Piall, & V. Marks. (1977). Development and application of a radioimmunoassay for methotrexate. British Journal of Cancer. 36(5). 608–617. 46 indexed citations

16.

Aherne, G. Wynne, E. M. Piall, & V. Marks. (1976). THE RADIOIMMUNOASSAY OF TRICYCLIC ANTIDEPRESSANTS. British Journal of Clinical Pharmacology. 3(4). 561–565. 22 indexed citations

17.

Piall, E. M., et al.. (1975). Development of a radioimmunoassay for morphine having minimal cross- reactivity with codeine. Journal of Endocrinology. 64(1). 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact